Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nouri Neamati

Showing results (21-30 of 239) with videos related to

Pageof 24
Sort By:
Pharmacological Reviews|October 16, 2024
Ironing Out the Mechanism of gp130 SignalingEssam Eldin A Osman, Nouri Neamati
Chemmedchem|August 8, 2006
Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitorsRaveendra Dayam, Tino Sanchez, Nouri Neamati
Chemmedchem|January 29, 2011
Allosteric inhibitor development targeting HIV-1 integraseLaith Q Al-Mawsawi, Nouri Neamati
Medicinal Research Reviews|February 24, 2006
HIV-1 integrase inhibitors: 2003-2004 updateRaveendra Dayam, Jinxia Deng, Nouri Neamati
Current Cancer Drug Targets|February 20, 2007
Small molecule inhibitors of Stat3 signaling pathwayJinxia Deng, Fedora Grande, Nouri Neamati
Bioorganic & Medicinal Chemistry Letters|August 16, 2006
Synthesis and anti-HIV-1 activity of a novel series of 1,4,2-benzodithiazine-dioxidesZdzisław Brzozowski, Franciszek Saczewski, Nouri Neamati
Advanced Drug Delivery Reviews|September 1, 2009
Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolismDivya Pathania, Melissa Millard, Nouri Neamati
Expert Opinion on Therapeutic Patents|February 10, 2010
Patented small molecule inhibitors of p53-MDM2 interactionJinxia Deng, Raveendra Dayam, Nouri Neamati
Theranostics|May 23, 2017
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory DiseasesHelen Ha, Bikash Debnath, Nouri Neamati
European Journal of Medicinal Chemistry|August 24, 2020
Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonistsDing Xue, Wenmin Chen, Nouri Neamati
Pageof 24

Showing results (21-30 of 239) with videos related to

Sort By:
Pageof 24
Pharmacological Reviews|October 16, 2024
Ironing Out the Mechanism of gp130 SignalingEssam Eldin A Osman, Nouri Neamati
Chemmedchem|August 8, 2006
Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitorsRaveendra Dayam, Tino Sanchez, Nouri Neamati
Chemmedchem|January 29, 2011
Allosteric inhibitor development targeting HIV-1 integraseLaith Q Al-Mawsawi, Nouri Neamati
Medicinal Research Reviews|February 24, 2006
HIV-1 integrase inhibitors: 2003-2004 updateRaveendra Dayam, Jinxia Deng, Nouri Neamati
Current Cancer Drug Targets|February 20, 2007
Small molecule inhibitors of Stat3 signaling pathwayJinxia Deng, Fedora Grande, Nouri Neamati
Bioorganic & Medicinal Chemistry Letters|August 16, 2006
Synthesis and anti-HIV-1 activity of a novel series of 1,4,2-benzodithiazine-dioxidesZdzisław Brzozowski, Franciszek Saczewski, Nouri Neamati
Advanced Drug Delivery Reviews|September 1, 2009
Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolismDivya Pathania, Melissa Millard, Nouri Neamati
Expert Opinion on Therapeutic Patents|February 10, 2010
Patented small molecule inhibitors of p53-MDM2 interactionJinxia Deng, Raveendra Dayam, Nouri Neamati
Theranostics|May 23, 2017
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory DiseasesHelen Ha, Bikash Debnath, Nouri Neamati
European Journal of Medicinal Chemistry|August 24, 2020
Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonistsDing Xue, Wenmin Chen, Nouri Neamati
Pageof 24